<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="372193">
  <stage>Registered</stage>
  <submitdate>18/01/2017</submitdate>
  <approvaldate>9/02/2017</approvaldate>
  <actrnumber>ACTRN12617000221358</actrnumber>
  <trial_identification>
    <studytitle>Effects of eye drops causing pupil dilatation on neonatal brain blood flow</studytitle>
    <scientifictitle>Impact of mydriatic eye drops on neonatal cerebral blood flow</scientifictitle>
    <utrn> U1111-1191-7692</utrn>
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>neonatal cerebral blood flow</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Studies of the normal brain and nervous system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Impact of mydriatic eye drops on neonatal cerebral blood flow.
-Fundus examination following installation of mydriatics is a routine practice in neonatal intensive care unit (NICU) for retinopathy of prematurity ( ROP ) examination, the purpose of this study is to evaluate any possible effect of mydriatic eye drops on cerebral blood flow of preterm infants.
-We will prospectively study   50 preterm neonates admitted to NICU, Dubai hospital  with a mean gestational age of 28 weeks (range 24-30 weeks ), birth weight (range 0.5 -2 kgm) at the post-conceptional age of 33 weeks, color Doppler flow study carried out immediately before and then one hour after installation of mydriatic eye drops for ROP examination .
We will investigate the peak systolic velocity(PSV), end diastolic velocity(EDV) and resistive index (RI)in both anterior and middle cerebral arteries as well as blood pressure, heart rate, respiratory rate, pain score and oxygen saturation Spo2.
-To attain the maximal and sustained mydriasis for proper fundus examination, at least two drugs are used namely phenylephrine hydrochloride 2.5% and tropicamide 0.5% eye drops.                                                                             
Phenylephrine has an alpha sympathomimetic agonist effect, readily absorbed from mucosa with an excessive vasopressor systemic response.
-The present investigation was designed to study the possible systemic effects of mydriatic eye drops-used for ROP examination- on cerebral blood flow in preterm babies.
-Cerebral blood flow measurements :
 All Pulsed-wave Doppler ultrasound studies to be performed by the same investigator (AA).Using Philips HD11XE (Philips Medical Systems, Eindhoven, The Netherlands).and a convex transducer (4-8MHz) in a quiet room.
15 cerebral blood flow velocity( CBFVs) records will be randomly selected and to be revised later by a radiologist who was blinded to the study to eliminate bias.
This protocol to be repeated two times for each patient, once before application of eye mydriasis and then an hour after ROP examination.
we will record the vital data for the babies namely heart rate ,SPO2, blood pressure , temperature and pain score again before and after the procedure.





</interventions>
    <comparator>no control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To study  proportion of participants with a rise in RI of more than 0.85 in anterior and middle cerebral arteries assessed using Doppler ultrasound.</outcome>
      <timepoint>Resistive index RI will be measured one hour after installation of phenyephrine eye drops 2.5% used routinely for pupil dilatation prior ROP examination in preterm infants.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>measurement of vital signs : blood pressure assessed by dinamap blood pressure monitor.</outcome>
      <timepoint>after one hour of installation of phenylephrine hydrochloride 2.5% eye drops .</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>to assess oxygen saturation in the right hand by pulse oximetry masimo device.</outcome>
      <timepoint>one hour after installation of phenylephrine hydrochloride 2.5 % eye drops.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>assessement of pain score by ( NIPS) pain assessement tool</outcome>
      <timepoint>after one hour of installation of phenylephrine hydrochloride 2.5% eye drops</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Preterm infants with gestational age at birth of 24 to 30 weeks admitted to NICU, Dubai hospital who are vitally stable at time of enrollment.</inclusivecriteria>
    <inclusiveminage>3</inclusiveminage>
    <inclusiveminagetype>Weeks</inclusiveminagetype>
    <inclusivemaxage>12</inclusivemaxage>
    <inclusivemaxagetype>Weeks</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1- Major congenital anomalies and  known syndromes.
2-Hemodynamically significant patent ductus arteriosus PDA.
3- Congenital or acquired hydrocephalus.
4- infants on inotropic support.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>The effect of phenylephrine hydrochloride 2.5% eye drops on neonatal cerebral blood flow has not been investigated before, accordingly sample size of 40-50 infants has been chosen to achieve a statistical significance being a pilot study.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>20/02/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>31/03/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/03/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United Arab Emirates</country>
      <state>dubai</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>ATEF ALSHAFEI</primarysponsorname>
    <primarysponsoraddress>NICU, DUBAI HOSPITAL
THIRD FLOOR.
ALBARAHA, Alkornisch street No.1.
DUBAI 7272.
UAE</primarysponsoraddress>
    <primarysponsorcountry>United Arab Emirates</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>DUBAI HOSPITAL</fundingname>
      <fundingaddress>NICU, DUBAI HOSPITAL.
THIRD FLOOR.
ALBARAHA, Alkornisch street No.1.
DUBAI 7272
UAE.</fundingaddress>
      <fundingcountry>United Arab Emirates</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Mahmoud Galal</sponsorname>
      <sponsoraddress>Nicu, Dubai hospital
third floor
Al-baraha, Alkornisch street. No.1
DUBAI 7272.
UAE</sponsoraddress>
      <sponsorcountry>United Arab Emirates</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>DUBAI HOSPITAL</othercollaboratorname>
      <othercollaboratoraddress>NICU,DUBAI HOSPITAL
THIRD FLOOR,
AL-BARAHA, Alkornisch street No.1.
DUBAI 7272
UAE.</othercollaboratoraddress>
      <othercollaboratorcountry>United Arab Emirates</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective of current study is to answer the question, Do the mydriatic eye drops used prior fundus examination in preterm infants affect cerebral blood flow ?.Mydriatic eye drops causing pupil dilatation have systemic vasoconstriction effects on different blood vessels in the gut, kidneys, and lungs. Studying the effects of routine NICU medications on cerebral blood flow is of paramount importance particularly preterm infants.

</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Dubai Scientific Research Ethics Committee DSREC</ethicname>
      <ethicaddress>DSREC
CONTINUOUS MEDICAL EDUCATION DEPARTMENT
RASHID MEDICAL LIBRARY
PO BOX 4545
DUBAI.
UAE</ethicaddress>
      <ethicapprovaldate>7/09/2016</ethicapprovaldate>
      <hrec>DSREC-08/2016-12</hrec>
      <ethicsubmitdate>7/07/2016</ethicsubmitdate>
      <ethiccountry>United Arab Emirates</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>atef alshafei</name>
      <address>NICU, DUBAI HOSPITAL
THIRD FLOOR,
Albarah, Alkornisch street .No.1.
DUBAI, 7272
UAE</address>
      <phone>+971561924270</phone>
      <fax />
      <email>ahalshafei@dha.gov.ae</email>
      <country>United Arab Emirates</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>ATEF ALSHAFEI</name>
      <address>NICU, DUBAI HOSPITAL
THIRD FLOOR,
Albaraha, Alkornisch street, No.1.
DUBAI, 7272.
UAE.</address>
      <phone>+971561924270</phone>
      <fax />
      <email>ahalshafei@dha.gov.ae</email>
      <country>United Arab Emirates</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>ATEF ALSHAFEI</name>
      <address>NICU, DUBAI HOSPITAL
THIRD FLOOR
Albarah, Alkornisc street, No.1.
DUBAI, 7272.
UAE.</address>
      <phone>+971561924270</phone>
      <fax />
      <email>ahalshafei@dha.gov.ae</email>
      <country>United Arab Emirates</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>ATEF ALSHAFEI</name>
      <address>NICU, DUBAI HOSPITAL
THIRD FLOOR.
Albarah, Alkornisch street, No.1.
DUBAI, 7272.
UAE.</address>
      <phone>+971561924270</phone>
      <fax />
      <email>ahalshafei@dha.gov.ae</email>
      <country>United Arab Emirates</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>